EMA clears Oryzon to launch HOPE-2 Phase II vafidemstat trial in Phelan-McDermid syndrome
Bitget2026/09/28 06:26- EMA cleared Oryzon Genomics to start the Phase IIa HOPE-2 trial of vafidemstat in Phelan-McDermid syndrome.
- Open-label, single-center study targets 12 adults in Spain, with 12 weeks of dosing and an option to extend to 24 weeks.
- Trial is partly funded through Oryzon’s VANDAM project under the EU-backed Med4Cure IPCEI health program.
- Spain’s Ministry of Science, Innovation and Universities, CDTI, and the EU’s NextGenerationEU are providing the public funding.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
